Literature DB >> 10866128

Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients.

C M Mastroianni1, M Lichtner, F Mengoni, C D'Agostino, G d'Ettorre, G Forcina, P Santopadre, A P Massetti, V Vullo.   

Abstract

Increased levels of soluble cell adhesion molecules (sCAM) have been reported in HIV-1 infection and may possibly contribute to altering the adhesion mechanisms of phagocytic cells. We evaluated the effect of highly active antiretroviral therapy (HAART) on plasma levels of sL-selectin, sE-selectin, intercellular cell adhesion molecule-1 (sICAM-1), sICAM-3, and vascular cell adhesion molecule-1 (sVCAM-1). Study participants included 22 HIV-1-infected patients with a CD4+ T-cell count/microl below 500 who were started on a HAART regimen and followed up for 9 months. After the initiation of therapy, plasma sL-selectin concentrations progressively decreased to normal ranges in the majority of our patients (P < 0.001), while no changes in sE-selectin were found. In all patients sICAM-1 remained relatively constant at significantly elevated concentrations during the 9 months of therapy. A significant reduction in plasma concentrations of both sICAM-3 and sVCAM-1 was found; however, the levels of these sCAM were not normalized by HAART and remained significantly elevated throughout the study (P < 0.001). The reduced release of sL-selectin could improve the ability of phagocitic cells to migrate in response to chemotactic stimuli after starting HAART. On the other hand, the persistent elevation of sICAM-1, sICAM-3, and sVCAM-1 could reflect continuous HIV-1-mediated immune activation, despite adequate control of plasma HIV-1 replication by therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866128     DOI: 10.1006/clim.2000.4865

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

Review 1.  Endothelial dysfunction in HIV infection.

Authors:  Bruno R Cotter
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

Review 2.  Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 3.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.

Authors:  A De Milito; S Aleman; R Marenzi; A Sonnerborg; D Fuchs; M Zazzi; F Chiodi; Fuchs D
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

5.  Regional gene expression of LOX-1, VCAM-1, and ICAM-1 in aorta of HIV-1 transgenic rats.

Authors:  Anne Mette Fisker Hag; Ulrik Sloth Kristoffersen; Sune Folke Pedersen; Henrik Gutte; Anne-Mette Lebech; Andreas Kjaer
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

6.  The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.

Authors:  Andrea De Luca; Katleen de Gaetano Donati; Manuela Colafigli; Alessandro Cozzi-Lepri; Amalia De Curtis; Andrea Gori; Laura Sighinolfi; Andrea Giacometti; Maria Rosaria Capobianchi; Alessandro D'Avino; Licia Iacoviello; Roberto Cauda; Antonella D'Arminio Monforte
Journal:  BMC Infect Dis       Date:  2013-09-03       Impact factor: 3.090

7.  Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.

Authors:  Rudolph L Gleason; Alexander W Caulk; Daniel Seifu; Ivana Parker; Brani Vidakovic; Helena Getenet; Getachew Assefa; Wondwossen Amogne
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.